Additionally, traditional immune therapies such as tumour necrosis factor-alpha (TNFα) [26], interleukin-2 (IL-2) [27], interferon-gamma (IFNγ) [28], and immune checkpoint inhibitors (ICIs) such as pembrolizumab, nivolumab, atezolizumab, ipilimumab, and relatlimab are central to melanoma treatment, and are also utilized intensively in this field [29,30,31,32,33]. This evidence concerns the gene IL2 and melanoma.